000212514 001__ 212514
000212514 005__ 20240229154913.0
000212514 0247_ $$2doi$$a10.1186/s13053-023-00245-5
000212514 0247_ $$2pmid$$apmid:36707860
000212514 0247_ $$2pmc$$apmc:PMC9883872
000212514 0247_ $$2ISSN$$a1731-2302
000212514 0247_ $$2ISSN$$a1897-4287
000212514 0247_ $$2altmetric$$aaltmetric:141896532
000212514 037__ $$aDKFZ-2023-00199
000212514 041__ $$aEnglish
000212514 082__ $$a610
000212514 1001_ $$0P:(DE-He78)d22bc86a498d1be5f5e75a7d5d0647e3$$aAhmad, Olfat$$b0$$eFirst author$$udkfz
000212514 245__ $$aThe complementary roles of genome-wide approaches in identifying genes linked to an inherited risk of colorectal cancer.
000212514 260__ $$aHeidelberg$$bSpringer$$c2023
000212514 3367_ $$2DRIVER$$aarticle
000212514 3367_ $$2DataCite$$aOutput Types/Journal article
000212514 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675066767_21995$$xReview Article
000212514 3367_ $$2BibTeX$$aARTICLE
000212514 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212514 3367_ $$00$$2EndNote$$aJournal Article
000212514 500__ $$a#LA:B062#EA:B062#
000212514 520__ $$aThe current understanding of the inherited risk of colorectal cancer (CRC) started with an observational clinical era in the late 19th century, which was followed by a genetic era starting in the late 20th century. Genome-wide linkage analysis allowed mapping several high-risk genes, which marked the beginning of the genetic era. The current high-throughput genomic phase includes genome-wide association study (GWAS) and genome-wide sequencing approaches which have revolutionized the conception of the inherited risk of CRC. On the one hand, GWAS has allowed the identification of multiple low risk loci correlated with CRC. On the other, genome-wide sequencing has led to the discovery of a second batch of high-to-moderate-risk genes that correlate to atypical familial CRC and polyposis syndromes. In contrast to other common cancers, which are usually dominated by a polygenic background, CRC risk is believed to be equally explained by monogenic and polygenic architectures, which jointly contribute to a quarter of familial clustering. Despite the fact that genome-wide approaches have allowed the identification of a continuum of responsible high-to-moderate-to-low-risk variants, much of the predisposition and familial clustering of CRC has not yet been explained. Other genetic, epigenetic and environmental factors might be playing important roles as well. In this review we aim to provide insights on the complementary roles played by different genomic approaches in allowing the current understanding of the genetic architecture of inherited CRC.
000212514 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000212514 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212514 650_7 $$2Other$$aCRC
000212514 650_7 $$2Other$$aCancer predisposition
000212514 650_7 $$2Other$$aGWAS
000212514 650_7 $$2Other$$aGenome-wide
000212514 650_7 $$2Other$$aHigh-risk gene
000212514 650_7 $$2Other$$aInherited Cancer
000212514 650_7 $$2Other$$aLow-risk gene
000212514 650_7 $$2Other$$aWGS
000212514 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$eLast author$$udkfz
000212514 773__ $$0PERI:(DE-600)2233352-6$$a10.1186/s13053-023-00245-5$$gVol. 21, no. 1, p. 1$$n1$$p1$$tHereditary cancer in clinical practice$$v21$$x1731-2302$$y2023
000212514 909CO $$ooai:inrepo02.dkfz.de:212514$$pVDB
000212514 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d22bc86a498d1be5f5e75a7d5d0647e3$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000212514 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000212514 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000212514 9141_ $$y2023
000212514 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000212514 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000212514 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-09
000212514 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-09
000212514 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:09:24Z
000212514 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:09:24Z
000212514 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-04-12T15:09:24Z
000212514 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000212514 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000212514 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000212514 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000212514 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000212514 9200_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000212514 980__ $$ajournal
000212514 980__ $$aVDB
000212514 980__ $$aI:(DE-He78)B062-20160331
000212514 980__ $$aI:(DE-He78)HD01-20160331
000212514 980__ $$aUNRESTRICTED